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Edited by Beat ImhofAbstract To identify the linear epitope for Fc-binding on the
bovine IgG2 Fc receptor (boFcc2R), peptides derived from the
membrane-distal extracellular domain (EC1) of boFcc2R corre-
sponding to the homologous region of human FcaRI were synthe-
sized. Binding of bovine IgG2 to the diﬀerent peptides was tested
by Dot-blot assay, and the peptide showing maximal binding was
further modiﬁed by truncation and mutation. The minimum eﬀec-
tive peptide 82FIGV85 located in the putative F–G loop of the
EC1 domain was found to bind bovine IgG2 speciﬁcally and in-
hibit the binding of bovine IgG2 to the receptor. The Phe82, Ile83
and Val85 residues within the linear epitope were shown to be
critical for IgG2-binding. Such functional epitope peptide should
be very useful for understanding the IgG-Fcc interaction and
development of FcR-targeting drugs.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Receptors for the Fc of immunoglobulins, Fc receptors
(FcRs), expressed on various immune cells play an important
role in immune regulation by providing a link between the hu-
moral immune response and cellular eﬀector functions [1].
Activation of FcR-bearing cells by antibodies or immune-com-
plexes depends on the activating and inhibitory FcRs involved
in immunoglobulin binding. The activating receptors initiate
inﬂammatory, cytolytic and phagocytic activities of immune
eﬀector cells through the cytoplasmic domain (FccRIIA) or
FcR c-chain that contains an immunoreceptor tyrosine-basedAbbreviations: boFcc2R, bovine IgG2 receptor; EC, extracellular do-
main; FcaRI, IgA Fc receptor; FcR, Fc receptor; HRP, horseradish
peroxidase; ITAM, immunoreceptor tyrosine-based activation motif;
ITIM, immunoreceptor tyrosine-based inhibitory motif; RBC, red
blood cell
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doi:10.1016/j.febslet.2006.01.060activation motif (ITAM) (FccRI and FccRIII), whereas the
inhibitory receptor FccRIIB harboring an immunoreceptor
tyrosine-based inhibitory motif (ITIM) inhibits ITAM-medi-
ated cellular activation upon cross-linking with the activating
receptors [2,3]. A recent study has identiﬁed the IgA Fc recep-
tor (FcaRI) as an inhibitory receptor. The inhibitory mecha-
nism involves recruitment of tyrosine phosphatase SHP-1 to
FcaRI on its targeting by serum IgA or anti-FcaRI Fab and
impairment of the Syk, LAT, and ERK phosphorylation in-
duced by type I IgE Fc receptor (FceRI) engagement. Con-
versely, sustained aggregation of FcaRI by multimeric
ligands stimulates cell activation by recruiting high amounts
of Syk and aborting SHP-1 binding [4]. Thus, imbalance of
the Fc receptor regulatory system may result in the develop-
ment of autoimmune diseases and allergy in humans, such as
autoimmune hemolytic anemia (AHA), idiopathic thrombocy-
topenia purpura (ITP), rheumatoid arthritis (RA) and asthma
[5]. Activating-type FcRs are essential for the development of
antibody-mediated allergy and autoimmunity, whilst inhibi-
tory receptors play an indispensable role in the suppression
of these diseases, suggesting that modulation of activating or
inhibitory FcRs is an ideal target for development of therapeu-
tic agents [3]. Anti-FcaRI Fab treatment has been shown to
suppress manifestations of allergic asthma in FcaRI transgenic
mice [4].
Recent structural analyses of crystalline receptor-Fc com-
plexes provide another possible approach for developing
FcR-targeting drugs. Atomic-level structural data are now
available for the extracellular (EC) domains of FccRIIA,
FccRIIB, FccRIIIB, FceRI and FcaRI [6]. The crystal struc-
ture of IgG1 Fc fragment-FccRIII complex reveals that
FccRIII binds the lower hinge region and the second constant
domain of the IgG heavy chain (Cc2) of the Fc fragment [7],
indicating a new way of designing small peptides that inhibit
the binding of IgG to the receptor. Indeed, peptides derived
from the human IgG have exhibited the capacity to interact
with to FcRs [8–10]. With respect to FcRs, ligand-binding re-
gions in the receptors have been proposed based on structural
and molecular analyses [6]. We hypothesize that a peptide de-
rived from the Fc-binding site of the receptor would be a better
candidate for downregulation of FcR-initiated inﬂammatory
responses.
Previously, we identiﬁed four distinct classes of FccRs in
cattle [11–14], three of them are homologous to those identiﬁedblished by Elsevier B.V. All rights reserved.
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vine IgG2 Fc receptor (boFcc2R), which is genetically more
closely related to a novel family of human proteins that in-
cludes FcaRI, killer cell inhibitory receptor (KIR) and leuko-
cyte Ig-like receptor (LIR) [12,16]. Although it shows a high
level of amino acid identity with FcaRI within the EC domains
and transmembrane regions, boFcc2R binds only bovine IgG2
but not IgG1 nor IgA [12]. As a unique class of FccR,
boFcc2R binds Fc in a distinct manner from the other FccRs
so-far characterized. The functional characterization of
boFcc2R showed that it binds bovine IgG2 via the mem-
brane-distal EC1 domain [17,18], whereas the others bind
IgG via the membrane-proximal EC2 domain [19,20]. It ap-
pears that the Fc-binding sites in the EC1 domain may be a
characteristic typical of many other members of the Fc recep-
tor gene family to which boFcc2R belongs [17,21,22].
In this study, we used boFcc2R as a model to investigate
whether linear epitopes exist on Fc receptors. The linear epi-
tope on boFcc2R involved in the binding of bovine IgG2
was identiﬁed and characterized using synthetic peptides.
The peptide corresponding to sequence 82–85 of boFcc2R in
the putative F–G loop of the EC1 domain was found to bind
bovine IgG2 speciﬁcally, in which the residues Phe82, Ile83 and
Val85 are critical for the binding of bovine IgG2.2. Materials and methods
2.1. Cells
COS-7 cells were obtained from the Institute for Animal Health,
UK, and maintained with DMEM medium (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS,
Invitrogen).
2.2. Peptide synthesis and conjugation
After alignment of the EC1 domain protein sequences of boFcc2R,
boFcaR and huFcaRI (NCBI protein Accession Nos. NP_001001138,
AAP41842 and CAA38089), six peptides corresponding to the se-
quence 14–90 of boFcc2R were designed according to the crystal struc-
ture of huFcaRI [23,24]. The peptides and their N-truncated,
C-truncated and Ala-substituted derivatives were synthesized by the
solid-phase peptide synthesis method as described previously [25] using
a Symphony Multiplex Peptide Synthesizer (Protein Technologies,
Inc., USA). Peptide purities were greater than 90% as assessed by
HPLC and mass spectrometry. During synthesis, a cysteine residue
was added at the N-terminal of all peptides except those that have a
cysteine residue in the position for conjugation. Peptides were conju-
gated to a carrier protein of IgG-free bovine serum albumin (BSA, Sig-
ma, St. Louis, MO, USA) using a hetero-bifunctional cross-linker
Sulfo-SMCC (Pierce Biotechnology Inc., Rockford, USA) according
to the manufacture’s instructions.
2.3. Construction of the expression plasmids
A cDNA for the complete coding region of boFcc2R [12] was sub-
cloned into the mammalian expression vector pcDNA3 (Invitrogen)
for expression of boFcc2R on the cell surface, whilst the cDNA encod-
ing the extracellular domain of boFcc2R was cloned into the prokary-
otic expression vector pET-28a (Novagen, Madison, WI, USA) for
production of the soluble recombinant protein. Both of the recombi-
nant expression plasmids, designated as pcboFc2R and pETboFc2R,
respectively, were identiﬁed by restriction enzyme digestions and veri-
ﬁed by sequencing.
2.4. Transfection
COS-7 cells were transfected with 1 lg of the BglII-linearized
pcboFc2R by Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instructions. After culture for 48 h at 37 C, the transfectedcells were detached and selected with 400 lg/ml G418 (Invitrogen) in a
96-well plate (Nunc). The G418-resistant clones were cloned and
screened for boFcc2R expression on the cell surface by Fc rosetting
analysis as described below.
2.5. Preparation of soluble boFcc2R
The extracellular domain of boFcc2R was expressed in Escherichia
coli (E. coli) BL21(DE3) transformed by pETboFc2R. The expressed
protein isolated from inclusion bodies was dissolved in 8 M urea solu-
tion and puriﬁed by Ni-chelation chromatography. The denatured pro-
tein was rapid diluted in a large volume of the refolding buﬀer
(100 mM Tris–HCl, pH 8.0, 400 mM L-arginine monohydrochloride,
2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidized glutathi-
one, 0.1 mM PMSF, and 0.1 mM NaN3) and refolded at 4 C for
60 h. After concentrated, the functional boFcc2R protein was then
recovered from the refolded solution by Superdex-75 column (Amer-
sham Biosciences Biotech, Uppsala, Sweden).
2.6. Preparation of bovine IgGs
Bovine IgG1 and IgG2 speciﬁc for chicken red blood cells (RBCs)
were prepared as described previously [11]. The puriﬁed bovine IgG1
and IgG2 were routinely conjugated to horseradish peroxidase
(HRP) with sodium periodate for the IgG-binding assay. Furthermore,
bovine IgG2 was titrated against 0.5% chicken RBCs to determine the
agglutination dose for RBC-sensitization.
2.7. IgG-binding assay
A Dot-blot assay was developed to test the binding of bovine IgG2
to the diﬀerent boFcc2R peptides. The BSA-coupled peptides were
blotted onto nitrocellulose membranes (Millipore, MA, USA) at
1 lg/dot, respectively, and 1 lg/dot of the carrier protein BSA and
the soluble boFcc2R were used as negative and positive controls,
respectively. After air drying, the membrane was blocked by 0.1% gel-
atin in 0.01 M phosphate-buﬀered saline (PBS, pH 7.2) containing
0.05% Tween 20 (PBST) at 37 C for 1 h, and then incubated with
10 lg/ml HRP-conjugated bovine IgG1 or IgG2 (HRP-IgG1/IgG2)
in PBST containing 0.1% gelatin at 37 C for 1 h followed by thorough
washing with PBST. Colour was developed using a 3-amino-9-ethylc-
arbazole (AEC) staining kit (Sino-America Biotechnology Company,
Luoyang, China) according to the manufacturer’s instructions. Col-
oured membranes were screened using a TSR-3000 plate Reader
(Bio-Dot, CA, USA), and data acquisition was conducted using AIS
software (Ver. 6.0, Bio-Dot).
In blocking assay, the BSA-coupled boFcc2R peptides were blotted
onto nitrocellulose membranes at 1 lg/dot, respectively. After gelatin
blocking, the membrane was pre-incubated with PBS, 5% bovine ser-
um, and 10 lg/ml puriﬁed bovine IgG2 at 37 C for 1 h, respectively.
The blocked membranes were then incubated with HRP-IgG2 as
described above.
2.8. Competitive ELISA on boFcc2R-coated plates
The inhibitory capacity of the synthesized peptide was measured by
the competitive ELISA method as described [26]. High-binding ELISA
plates (Nunc, Copenhagen, Denmark) were coated with the recombi-
nant boFcc2R (rbo2R) protein at 50 nM followed by blocking with
0.1% gelatin. In the competition assay, 50 nM of HRP-IgG2 was
pre-incubated with various concentrations(10–640 lM) of the synthetic
peptide at 4 C for 2 h. The mixed samples were then transferred,
respectively, to the rbo2R-coated plates for IgG2 binding with an incu-
bation of 1 h at 37 C. 3,3 0,5,5 0-Tetramethylbenzidine (TMB) (Sigma)
was used as the chromogen for the colour development, and absor-
bance at 450 nm was measured. A peptide shown no binding of bovine
IgG2 was used as a negative control to subtract the unspeciﬁc inhibi-
tion eﬀect. The samples were duplicated at each peptide concentration,
and all experiments were carried out in triplicate. Binding of bovine
IgG2 to the coated rbo2R without the inhibiting peptide (B0) was con-
sidered as 100% binding. For each peptide concentration, the inhibi-
tion percentage (Ic%) was calculated as Ic% = (Bn  Bi)/B0 · 100%,
where Bi and Bn are IgG2 binding of the inhibiting and negative pep-
tides, respectively, at c peptide concentration. Based on c and the aver-
age Ic% values, a c vs. Ic% curve was constructed and analysed by
Mattlab to calculate the amount of added peptide required to inhibit
IgG2 binding by 50% (IC50).
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Fc rosetting assay was performed as described previously [12].
Brieﬂy, the boFcc2R-transfected COS-7 cells cultured in 96-well plates
were washed gently and incubated in serum free medium at 37 C for
2 h to elute the bound IgG prior to rosetting analysis. Meanwhile,
chicken RBCs were sensitized with the semi-agglutination dose of bo-
vine IgG2 (0.15 lM) at 4 C for 2 h. The sensitized RBCs were then
suspended at 0.5% in the serum free medium, added onto the COS-7
cell monolayer followed by incubation for 10 min at 37 C plus an
additional 35 min at room temperature. After washing gently with
PBS, cells were ﬁxed with methanol and detected by HRP-conjugated
goat anti-bovine IgG2 antibody (Serotec, Oxford, UK) followed by
AEC staining. The stained cells were examined by microscopy and
COS-7 cells that bound 5 or more sensitized RBCs were counted as
rosetting positive. The percentage of rosette formation was obtained
by counting the rosettes on the transfected COS-7 cells in three high-
power (200·) ﬁeld.
For the inhibition of Fc rosetting, 0.5% of the IgG2-sensitized
RBCs were pre-incubated, respectively, with various concentrations
of the inhibiting peptide (10–640 lM) or rbo2R (0.1–6.4 lM) at
4 C for 2 h, and then applied to the transfected COS-7 cells for ro-
sette formation as described above. The peptide with no binding of
bovine IgG2 was used as a negative control to subtract the unspeciﬁc
inhibition eﬀect. The samples were duplicated at each peptide concen-
tration, and all experiments were carried out in triplicate. The num-
ber of rosettes without the peptide or rbo2R (B0) in three high-power
(200·) ﬁeld was considered as 100% binding, and the IC50 values of
the inhibiting peptide and rbo2R on Fc rosetting were calculated as
above.3. Results
3.1. Binding of bovine IgG2 to the boFcc2R peptides
Based on the alignment of the EC1 domain protein
sequences of boFcc2R, boFcaR and huFcaRI (Fig. 1), six
peptides covering, respectively, the putative A–B, B–C, C–C 0,Fig. 1. Alignment of the protein sequences of the EC1 domains of boFcc2R,
AAP41842, and CAA38089, respectively). The black highlights indicate that t
of amino acids. b-Sheet regions of huFcaRI EC1 domain (designated A to G
previous report [25].
Table 1
Characteristics of synthetic boFcc2R peptides
Name Sequencea Length (aa) Mass
bo2R1 14(C)AEPSSVVPLGSSVTIL29 17 1658.8
bo2R2 30CQGPPNTKSFSL41 12 1278.3
bo2R3 42(C)NKEGDSTPWNIH53 13 1500.5
bo2R4 54(C)PSLEPWDKANFF65 13 1553.6
bo2R5 66(C)ISNVREQQAGRYH78 14 1660.7
bo2R6 79CSHFIGVNWSEP90 12 1375.4
aThe Cys residue added to the N-terminus of the peptides for conjugation is
bThe binding of bovine IgG2 to the BSA-conjugated peptide was tested by the
to the peptide, and ‘‘’’ means that binding was not detected.
cThe putative position was assigned according to the crystal structure of huD–E, E–F and F–G loops of the EC1 domain were synthesized
to map the binding sites for bovine IgG2 on boFcc2R (Table
1). The binding of bovine IgG1 or IgG2 to the diﬀerent
peptides was tested using a Dot-blot assay. Results showed
that HRP conjugated-IgG2 (HRP-IgG2) only bound to the
sixth peptide bo2R6 79CSHFIGVNWSEP90 corresponding to
the putative F–G loop, whereas no binding of HRP-IgG1 to
any peptide was found (Fig. 2A). Moreover, binding of
HRP-IgG2 to the bo2R6 peptide could be blocked by bovine
serum as well as the puriﬁed bovine IgG2 (Fig. 2B).
3.2. Determination of minimal eﬀective peptide for IgG2 binding
The bo2R6 peptide found to interact with bovine IgG2
was then truncated from both ends to identify the shortest
eﬀective peptide for IgG2 binding. N-terminal amino acid
residues were ﬁrst truncated from the bo2R6 peptide one
by one, with the exception of Cys79 that was used to link
the peptide to the carrier protein and the N-truncated pep-
tides were then examined for bovine IgG2 binding (Table
2). Results showed that deletions of Ser80 and His81 residues
from the peptide did not apparently aﬀect its binding of bo-
vine IgG2, but further truncations led to a complete loss of
its Fc-binding capability (Fig. 3A). The peptide 2R6N-2,
retaining the IgG2-binding ability, was subsequently used
for further C-terminal truncations resulting in a series of
C-truncated peptides (Table 3). The C-truncated peptides
were shown to bind bovine IgG2 eﬀectively till the Val85 res-
idue was removed (Fig. 3B). That indicated the four-residue
peptide 82FIGV85 is the minimal eﬀective peptide for bovine
IgG2 binding and considered as the linear epitope for Fc
binding on boFcc2R located in the putative F–G loop of
the EC1 domain of boFcc2R.boFcaR, and huFcaRI (NCBI protein Accession Nos. NP_001001138,
wo or three sequences are identical, and dotted lines represent deletions
) are indicated by blank arrows below the sequence according to the
(Da) pI value IgG2 bindingb Predicted positionc
3 3.30  A–B loop
9 9.30  B–C loop
4 5.24  C–C0 loop
7 4.11  D–E loop
7 9.15  E–F loop
6 5.15 + F–G loop
listed in parentheses.
Dot-blot assay. ‘‘+’’ represents speciﬁc binding of bovine IgG2 bound
FcaRI and the alignment of boFcc2R and huFcaRI sequences.
Fig. 2. Binding of bovine IgG2 to the boFcc2R peptides. The BSA-coupled boFcc2R peptides were blotted onto nitrocellulose membranes at 1 lg/
dot using recombinant boFcc2R (rbo2R) and the carrier protein of BSA as positive and negative controls, respectively. After blocking with 0.1%
gelatine, the membranes were incubated with HRP-IgG1 or HRP-IgG2 at 37 C for 1 h followed by AEC staining (A). To test the speciﬁcity of IgG2
binding, the peptide-blotted membranes were pre-incubated, respectively, with 10 lg/ml of puriﬁed bovine IgG2, 5% bovine serum, or 0.1% gelatine
at 37 C for 1 h, and then detected by HRP-IgG2 as above (B). The coloured membranes were screened under a TSR-3000 Reader, and relative
optical density (ROD) values were analysed by AIS software.
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To identify the crucial residues for bovine IgG2 binding in this
linear epitope, the amino acid residues within the peptide 6N2-
C5 were sequentially substituted by alanine (Table 4). TheDot-blot result showed that the replacement of Phe82, Ile83 or
Val85 with Ala abolished its IgG2-binding capability, while the
substitution of Gly84 had a little eﬀect on binding (Fig. 3C), sug-
gesting that the Phe82, Ile83 and Val85 residues within the linear
epitope are critical for bovine IgG2 binding on boFcc2R.
Table 2
N-terminal truncation of the bo2R6 peptide for bovine IgG2 binding
Name Sequencea Length (aa) Mass (Da) pI value IgG2 bindingb
2R6-N1 81(C)HFIGVNWSEP90 11 1288.39 5.15 +
2R6-N2 82(C)FIGVNWSEP90 10 1151.25 3.15 +
2R6-N3 83(C)IGVNWSEP90 9 1004.08 3.15 
2R6-N4 84(C)GVNWSEP90 8 890.93 3.15 
2R6-N5 85(C)VNWSEP90 7 833.88 3.15 
2R6-N6 86(C)NWSEP90 6 734.75 3.15 
aThe Cys residue at N-terminus of the peptides for conjugation is listed in parentheses.
bThe binding of bovine IgG2 to the BSA-conjugated peptide was tested by the Dot-blot assay. ‘‘+’’ represents bovine IgG2 bound to the peptide
speciﬁcally, and ‘‘’’ means the binding was not detected.
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The peptide 6N2-C5 was used to evaluate the inhibition ef-
fect on bovine IgG2 binding to boFcc2R. In the competitive
ELISA, the 6N2-C5 peptide inhibited the binding of bovine
IgG2 to the soluble boFcc2R coated on the plate, whereas
the control peptide bo2R1 had little eﬀect on the IgG2 binding.
The IC50 value of 6N2-C5 peptide was calculated to be
27.35 lM after unspeciﬁc inhibition of the control peptide
was subtracted (Fig. 4).
3.5. Inhibition of IgG2 binding to boFcc2R on the cell surface
In order to evaluate the eﬀectiveness of the peptide in inhib-
iting the IgG2 binding to boFcc2R on the cell surface, COS-7
cells were transfected by boFcc2R cDNA with transfection
eﬃciencies in the range of 20–45% as determined by Fc roset-
ting. After antibiotic selection and cloning, transfected COS-7
cells with stable surface expression of boFcc2R were obtained
and these showed 90% rosetting with IgG2-sensitized RBCs.
In the inhibition assay, the inhibiting ability of the synthetic
peptide on rosette formation was determined and compared
with the recombinant boFcc2R protein. Fig. 5 showed that
the peptide 6N2-C5 inhibited the binding of bovine IgG2-sen-
sitized RBCs on the transfected COS-7 cells with IC50 value of
139.08 lM, which was about 480-fold less than that of the in-
tact receptor (IC50 = 0.29 lM). As a negative control, the pep-
tide 2R1 showed essentially no inhibition eﬀect on the rosette
formation at each concentration.4. Discussion
The extracellular regions of FccRs share the same overall
heart-shaped structure in which the two domains are positioned
at an acute angle to each other and share a large interface. The
EC1 and EC2 domains of all the receptors are each arranged
into an identical overall immunoglobulin-fold composed of
b-strands labelled as AA 0BCC 0EFG from the amino-terminus.
For the FccRs and FceRI, the ligand-binding site is present at
the top of the EC2 domain. In FcaRI, the EC1-EC2-domain
arrangement is reversed, and the ligand-interaction site is pres-
ent at the top of the EC1 domain [6]. In the present report, we
ﬁrstly describe a linear epitope for immunoglobulin-binding
on an FcR. The minimal eﬀective peptide FIGV corresponding
to the sequence 82–85 of boFcc2R possesses binding capability
for bovine IgG2 and is located in the putative F–G loop of the
EC1 domain. The result is in good agreement with previous
studies characterizing the ligand-binding site on boFcc2R as
well as on huFcaRI [18,27]. Mutational analysis of this region
showed that the Phe82 and Trp87 residues of boFcc2R are crit-ical for bovine IgG2 binding [18]. In the IgG-binding assay,
truncation of the Phe82 residue led to complete loss of bovine
IgG2 binding to the peptide. However, we found the Trp87-
truncated peptide still maintained a weaker-binding ability for
bovine IgG2 suggesting this residue might not play the crucial
role in ligand binding.
It had previously been shown that boFcc2R shared various
characteristics with huFcaRI, which further distinguished it
from other FccRs. In the EC1 domain of huFcaRI, the resi-
dues of Tyr35 in the B-C loop, and Tyr81, Arg82 and His85 in
the F–G loop have been identiﬁed as necessary for human
IgA binding [27,28]. It is suggested that the residues Phe82
and Val85 within the linear epitope for Fc binding on
boFcc2R, which are identiﬁed as critical residues for IgG2
binding, are analogous to Arg82 and His85 of huFcaRI after
comparison of the EC1 sequences. In addition, the residues
Ile83 were also considered as essential for bovine IgG2 binding
because the substitution of Ile83-Ala abolished IgG2-binding
capability of the peptide. Although the residues Tyr35 in the
B-C loop of huFcaRI is important for IgA binding, bovine
IgG2 binding to the peptide 2R2 30QGPPNTKSFSL41 derived
from the putative B-C loop was not found in the IgG-binding
assay. Recently, the bovine IgA Fc receptor (boFcaR) was
cloned and characterized, which shows high homology to huF-
caRI and boFcc2R [29]. The residue Tyr35 in the putative B-C
loop of boFcaR EC1 domain was shown to be essential for bo-
vine IgA binding in contrast to boFcc2R [30]. In addition, the
corresponding residue Phe35 in equine FcaR is also critical for
binding of equine IgA indicating its importance in ligand bind-
ing, and is probably a key feature of the FcaR-IgA interaction
[31]. Although Ala-substitutions in the F–G loop of boFcaR
did not abolish bovine IgA binding [30], the residues in this re-
gion may also contribute somewhat to the interaction with li-
gand and need to be investigated further.
It would be very helpful to map the FcR-binding sites on bo-
vine IgG2 as well as IgA for understanding the molecular basis
of the Fcc-FccR interaction. The huFcaRI-binding site on IgA
was shown not to be located in the lower hinge region, as it is
with IgG, but located at the Ca2/Ca3 interface [32,33]. Because
of a distinctive six-amino acid deletion in bovine IgG2 within
the lower hinge region, in which it is considered the FccR-
binding motif normally exists [19], there has been co-adapta-
tion to utilize a receptor of the huFcaRI type. Therefore, it
is suggested that the FccR-binding site on bovine IgG2 may
perhaps be located at the Cc2/Cc3 boundary similar to that
of human IgA [18]. The precise residues on bovine IgG2
involved in FccR binding can readily be further identiﬁed
and characterized as the recombinant bovine IgG2 is now
available.
Fig. 3. IgG2 binding of the bo2R6 peptide derivatives. The N-truncated (A), C-truncated (B), and Ala-substituted (C) peptides derived from bo2R6
were blotted onto nitrocellulose membranes and detected by HRP-IgG2 as described as above. The coloured membranes were then screened by the
TSR-3000 Reader, and the ROD values were obtained.
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binding of bovine IgG2 to the soluble boFcc2R and the cell
surface one expressed on the transfected COS-7 cells. How-ever, a much higher concentration of the peptide was needed
for the rosette inhibition compared with the intact soluble
receptor. The main reason might be that this epitope peptide
Table 3
C-terminal truncation of the 2R6N-2 peptide for bovine IgG2 binding
Name Sequencea Length (aa) Mass (Da) pI value IgG2 bindingb
6N2-C1 82(C)FIGVNWSE89 9 1054.14 3.25 +
6N2-C2 82(C)FIGVNWS88 8 925.03 5.16 +
6N2-C3 82(C)FIGVNW87 7 837.96 5.23 +
6N2-C4 82(C)FIGVN86 6 651.76 5.12 +
6N2-C5 82(C)FIGV85 5 537.66 5.20 +
6N2-C6 82(C)FIG84 4 438.53 5.23 
aThe Cys residue at N-terminus of the peptides for conjugation is listed in parentheses.
bThe binding of bovine IgG2 to the BSA-conjugated peptide was tested by the Dot-blot assay. ‘‘+’’ represents bovine IgG2 bound to the peptide
speciﬁcally, and ‘‘’’ means the binding was not detected.
Table 4
Ala-substitution of the 6N2-C5 peptide for bovine IgG2 binding
Name Sequencea Length (aa) Mass (Da) pI value IgG2 bindingb
6N2C3-F 82(C)AIGV85 5 461.56 5.20 
6N2C3-I 82(C)FAGV85 5 495.58 5.20 
6N2C3-G 82(C)FIAV85 5 551.68 5.20 +
6N2C3-V 82(C)FIGA85 5 509.60 5.23 
aThe Cys residue at N-terminus of the peptides for conjugation is listed in parentheses. The substituted Ala residue was in bold.
bThe binding of bovine IgG2 to the BSA-conjugated peptide was tested by the Dot-blot assay. ‘‘+’’ represents bovine IgG2 bound to the peptide
speciﬁcally, and ‘‘’’ means the binding was not detected.
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Fig. 4. Inhibition of IgG2 binding to soluble boFcc2R. HRP-IgG2
was pre-incubated, respectively, with the peptide 6N2-C5 at diﬀerent
concentrations (10–640 lM) at 4 C for 2 h using bo2R1 peptide as a
negative control. The samples were then applied to rbo2R-coated
plates for IgG2 binding with an incubation of 1 h at 37 C followed by
colour development, and absorbance of the samples was measured at
450 nm. The amount of 6N2-C5 peptide that gives 50% inhibition
(IC50) of IgG2 binding to the soluble boFcc2R was calculated based on
the curve of the inhibition percentage (Ic%) against the peptide
concentration as described in Section 2. Ic% values of the peptides were
shown as means ± S.D. on the curve.
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Fig. 5. Inhibition of Fc rosetting by the peptide 6N2-C5. IgG2-
sensitized RBCs were pre-incubated with various concentrations of the
6N2-C5 peptide (10–640 lM) or rbo2R (0.1–6.4 lM) at 4 C for 2 h,
and then applied to the transfected COS-7 cells for rosette formation.
Rosettes on the transfected COS-7 cells in three high-power ﬁelds
(200·) were counted under a light microscope, and the IC50 values of
rosette formation for the peptide and rbo2R were calculated as
described above. The peptide bo2R1 was used as a negative control
peptide to subtract the unspeciﬁc inhibition eﬀect. The inhibition
percentages (Ic%) of peptides or rbo2R were shown as means ± S.D.
on the curve.
G. Zhang et al. / FEBS Letters 580 (2006) 1383–1390 1389with lower molecular weight has less aﬃnity to bovine IgG2. It
is also suggested that boFcc2R possess multiple regions con-
tributing to the ligand binding except for the F–G loop in its
EC1 domain, which was not detected by synthetic peptides.
Furthermore, the solubility of the peptide may also inﬂuence
its inhibition eﬀect on IgG2-binding to boFcc2R. The Fc-bind-
ing epitope peptide showed the capability of modulating the
interaction of immunoglobulins and FcRs, and thus should as-
sist in the design of drugs with a potential for regulating anti-
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